Schlessinger Joseph 4
4 · Inozyme Pharma, Inc. · Filed Jul 28, 2020
Insider Transaction Report
Form 4
Schlessinger Joseph
10% Owner
Transactions
- Conversion
Series A Convertible Preferred Stock
2020-07-28−100,000→ 0 total→ Common Stock (13,381 underlying) - Conversion
Common Stock
2020-07-28+13,381→ 286,479 total
Footnotes (1)
- [F1]On July 28, 2020, the Series A Convertible Preferred Stock automatically converted into Common Stock on a 7.4730-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.